Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MDGL Madrigal Pharmaceuticals

Not Yet Opened 06-23 16:00:00 EDT

513.43

+0.55

+0.11%

盘后513.43

+0.000.00%

17:39 EDT

High522.00	Low507.57	Vol266.38K
Open513.36	D1 Closing512.88	Amplitude2.81%
Mkt Cap11.84B	Tradable Cap5.65B	Total Shares23.06M
T/O136.80M	T/O Rate2.42%	Tradable Shares11.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MDGL","market":"US","secType":"STK","nameCN":"Madrigal Pharmaceuticals","latestPrice":513.43,"timestamp":1782244800000,"preClose":512.88,"halted":0,"volume":266383,"hourTrading":{"tag":"盘后","latestPrice":513.43,"preClose":513.43,"latestTime":"17:39 EDT","volume":6763,"amount":3472317.67,"timestamp":1782250798416,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0010723756044297974,"floatShares":11000087,"shares":23055522,"eps":-13.421304,"marketStatus":"Not Yet Opened","change":0.55,"latestTime":"06-23 16:00:00 EDT","open":513.36,"high":522,"low":507.57,"amount":136804319.4375,"amplitude":0.028135,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-13.421304,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782288000000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":512.88,"preHourTrading":{"tag":"盘前","latestPrice":512.77,"preClose":512.88,"latestTime":"08:10 EDT","volume":9,"amount":4614.93,"timestamp":1782216650085,"change":-0.11,"changeRate":-0.000214,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":513.43,"preClose":513.43,"latestTime":"17:39 EDT","volume":6763,"amount":3472317.67,"timestamp":1782250798416,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.808893,"impliedVol":0.5491,"impliedVolPercentile":0.3785},"requestUrl":"/m/hq/s/MDGL/wiki","defaultTab":"wiki","newsList":[{"id":"2645077144","title":"Madrigal Pharmaceuticals grants 1,397 inducement RSUs to five new employees under 2025 plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2645077144","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645077144?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:05","pubTimestamp":1782158741,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals granted 1,397 time-based restricted stock units to five new non-executive employees on June 15, 2026.Awards were issued under the company’s 2025 Inducement Plan.Restricted stock units vest in four equal installments on each of the first through fourth anniversaries of the grant date.Vesting is contingent on continued employment through each vesting date.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL5rzlyS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0314104364.USD","IE00BN0W2V16.EUR","SG9999014013.SGD","BK4112","MDGL","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4588","SG9999014005.SGD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4585","NDAQ","LU2095319765.USD","IE00BGHQF748.EUR","LU2210149790.SGD","SG9999014021.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645077971","title":"Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645077971","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645077971?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:05","pubTimestamp":1782158700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUABJKSX0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","MDGL","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645003282","title":"Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645003282","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645003282?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:05","pubTimestamp":1782158700,"startTime":"0","endTime":"0","summary":"CONSHOHOCKEN, Pa., June  22, 2026  (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-asso","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/22/3315603/0/en/Madrigal-Pharmaceuticals-Announces-Grants-of-Inducement-Awards-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","MDGL","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644460729","title":"Madrigal Pharmaceuticals adopts nonqualified deferred compensation plan effective Aug. 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2644460729","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644460729?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:07","pubTimestamp":1781726833,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals shareholders adopted a 2026 Stock Plan at the June 17 annual meeting.Shareholders also adopted a 2026 Employee Stock Purchase Plan at the same meeting.The board adopted a Nonqualified Deferred Compensation Plan, effective Aug. 1, for selected executives and non-employee directors.Eligible employees can defer up to 60% of base salary, up to 95% of the following year’s cash performance bonus.Deferred balances are payable on separation from service in a lump sum or installments of up to 10 years, or at an elected in-service date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Anal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL4KNWm2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","MDGL","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642284369","title":"Madrigal Pharmaceuticals Is Maintained at Neutral by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2642284369","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642284369?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:20","pubTimestamp":1781180400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDGL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 11, 2026 08:20 ET (12:20 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642281042","title":"BofA Securities Adjusts Madrigal Pharmaceuticals Price Target to $542 From $550","url":"https://stock-news.laohu8.com/highlight/detail?id=2642281042","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642281042?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:16","pubTimestamp":1781180201,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals (MDGL) has an average rating of Buy and mean price target of $678.80, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641284071","title":"A Look At Madrigal Pharmaceuticals (MDGL) Valuation After New Rezdiffra Data And Analyst Upgrades","url":"https://stock-news.laohu8.com/highlight/detail?id=2641284071","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641284071?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:26","pubTimestamp":1780691180,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals (MDGL) is back in focus after new Phase 3 and real world data presented at the EASL Congress 2026 linked its MASH drug Rezdiffra to improved liver and cardiovascular risk markers.\nSee our latest analysis for Madrigal Pharmaceuticals.\nDespite a recent pullback, including a 7 day share price return of down 4.5% and some profit taking after insider sales, Madrigal’s 1 year total shareholder return of about 80% and 5 year total shareholder return of over 3.5x suggest...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-new-1","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-new-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641162385","title":"Madrigal grants 6,881 inducement RSUs to 20 new employees under 2025 plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2641162385","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641162385?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:06","pubTimestamp":1780603578,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals granted 6,881 time-based restricted stock units to 20 new non-executive employees under its 2025 Inducement Plan.Restricted stock units vest in four equal annual installments over four years, subject to continued employment.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL3Pxs1k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00B3QW5Z07.USD","LU0314104364.USD","BK4112","IE00BN0W2W23.USD","LU2210150020.SGD","BK4585","SG9999014013.SGD","LU2095319765.USD","NDAQ","IE00BN0W2V16.EUR","IE00BKPKM429.USD","SG9999014039.USD","IE00BN0W2T93.GBP","LU2210149790.SGD","SG9999014005.SGD","BK4139","IE00BGHQF748.EUR","BK4588","MDGL","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641316289","title":"Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641316289","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641316289?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:05","pubTimestamp":1780603500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nTUA2QBPFY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDGL","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641162530","title":"Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641162530","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641162530?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:05","pubTimestamp":1780603500,"startTime":"0","endTime":"0","summary":"CONSHOHOCKEN, Pa., June  04, 2026  (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-ass","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/04/3307086/0/en/Madrigal-Pharmaceuticals-Announces-Grants-of-Inducement-Awards-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","MDGL","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640315668","title":"Madrigal Pharmaceuticals (MDGL) Is Down 7.5% After New Rezdiffra MASH Cardiometabolic Data Release – Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2640315668","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640315668?lang=en_us&edition=fundamental","pubTime":"2026-06-04 17:36","pubTimestamp":1780565795,"startTime":"0","endTime":"0","summary":"In late May 2026, Madrigal Pharmaceuticals reported new Phase 3 and real‑world data at the EASL Congress showing its MASH drug Rezdiffra lowered cardiovascular risk markers, improved liver risk scores in cirrhotic patients, and reduced liver stiffness in routine clinical practice.\nThese findings highlight Rezdiffra’s potential to address both liver disease progression and broader cardiometabolic risk, adding clinical depth beyond traditional histologic endpoints in MASH.\nWe’ll now examine...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/madrigal-pharmaceuticals-mdgl-is-down-75-after-new-rezdiffra","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/madrigal-pharmaceuticals-mdgl-is-down-75-after-new-rezdiffra","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4588","MDGL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640290190","title":"Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640290190","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640290190?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:00","pubTimestamp":1780488000,"startTime":"0","endTime":"0","summary":"CONSHOHOCKEN, Pa., June  03, 2026  (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 47th Annual Global Goldman Sachs Health Ca","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/03/3305993/0/en/Madrigal-Pharmaceuticals-to-Participate-in-the-47th-Annual-Global-Goldman-Sachs-Health-Care-Conference-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BSNM7G36.USD","LU2237443978.SGD","LU2750360997.AUD","MDGL","LU2237443382.USD","BK4550","LU1868836914.USD","LU2237443465.HKD","LU2237443549.SGD","LU2750360641.GBP","LU1804176565.USD","LU0251131958.USD","LU0868494617.USD","LU1894683264.USD","XBI","LU0061475181.USD","BK4127","LU0345770308.USD","IE00BFXG1179.USD","LU0742534661.SGD","IE0034235188.USD","IE0002270589.USD","LABU","LU0942090050.USD","BK4516","BK4504","GSX","LU2471134796.USD","LU1668664300.SGD","LU1868836757.USD","LU2471134952.CNY","BK4552","LU0096364046.USD","XLV","LU0048573561.USD","LU1868836591.USD","LU2237443622.USD","LU1868837300.USD","IE0004086264.USD","LU0345770993.USD","BK4533","LU1894683348.USD","LU1791807156.HKD","BK4139","IE0004091025.USD","LU2237438978.USD","BK4588","LU2265009873.SGD","LU2237443895.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640540998","title":"Madrigal CMO David Soergel disposes of 1,042 common shares worth $516,763.08","url":"https://stock-news.laohu8.com/highlight/detail?id=2640540998","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640540998?lang=en_us&edition=fundamental","pubTime":"2026-06-02 07:49","pubTimestamp":1780357783,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals Chief Medical Officer David Soergel sold 1,042 common shares on June 1, 2026 at USD 495.74.The sale was executed under a Rule 10b5-1 trading plan adopted on March 2, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDLb02Nqd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Madrigal CMO David Soergel disposes of 1,042 common shares worth $516,763.08","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","MDGL","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639869030","title":"A Look At Madrigal Pharmaceuticals (MDGL) Valuation After New Phase 3 And Real World Rezdiffra MASH Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2639869030","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639869030?lang=en_us&edition=fundamental","pubTime":"2026-05-29 00:14","pubTimestamp":1779984896,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals (MDGL) drew fresh attention after releasing new Phase 3 and real world data on its MASH drug Rezdiffra, ahead of detailed presentations at the EASL Congress 2026 in Barcelona.\nSee our latest analysis for Madrigal Pharmaceuticals.\nThe latest Rezdiffra data appear to be feeding into sentiment, with Madrigal’s 90 day share price return of 18.35% contrasting with a year to date share price decline of 11.15%, while the 1 year total shareholder return of 94.81% points to...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-new","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mdgl/madrigal-pharmaceuticals/news/a-look-at-madrigal-pharmaceuticals-mdgl-valuation-after-new","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4588","BK4585","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638664012","title":"Analyst Reiterates Buy on Madrigal Pharmaceuticals, Maintains $620 Price Target on Strengthened Rezdiffra MASH and Cardiometabolic Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2638664012","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638664012?lang=en_us&edition=fundamental","pubTime":"2026-05-28 18:15","pubTimestamp":1779963324,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Madrigal Pharmaceuticals today and set a price target of $620.00. Andrew Fein has gi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-madrigal-pharmaceuticals-maintains-620-price-target-on-strengthened-rezdiffra-mash-and-cardiometabolic-data-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-madrigal-pharmaceuticals-maintains-620-price-target-on-strengthened-rezdiffra-mash-and-cardiometabolic-data-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638958507","title":"Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients With Mash","url":"https://stock-news.laohu8.com/highlight/detail?id=2638958507","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638958507?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:00","pubTimestamp":1779883206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nTUABZS6XX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","MDGL","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638551159","title":"Analysts Are Bullish on Top Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Edgewise Therapeutics (EWTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638551159","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638551159?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:40","pubTimestamp":1779795643,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Madrigal Pharmaceuticals (MDGL) and Edgewise Therape...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-madrigal-pharmaceuticals-mdgl-edgewise-therapeutics-ewtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-madrigal-pharmaceuticals-mdgl-edgewise-therapeutics-ewtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","BK4007","EWTX","BK4585","BK4588","MDGL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637347817","title":"Madrigal director Richard S. Levy disposes of USD 2.4 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2637347817","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637347817?lang=en_us&edition=fundamental","pubTime":"2026-05-23 06:02","pubTimestamp":1779487352,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals director Richard S. Levy sold 5,642 shares of common stock on May 22, 2026.Sales were executed at weighted average prices ranging from $506.68 to $519.98 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDLb2WQSS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Madrigal director Richard S. Levy disposes of USD 2.4 million common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDGL","BK4585","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637512873","title":"Madrigal Pharmaceuticals grants 5,308 inducement RSUs to 15 new employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2637512873","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637512873?lang=en_us&edition=fundamental","pubTime":"2026-05-22 04:06","pubTimestamp":1779393986,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals granted 5,308 time-based restricted stock units to 15 new non-executive employees on May 15, 2026 under its 2025 Inducement Plan.The awards vest in four equal annual installments on the first through fourth anniversaries of the grant date.Vesting is contingent on continued employment through each vesting date.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL12P1dv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","MDGL","SG9999014021.USD","BK4585","BK4139","IE00BN0W2V16.EUR","NDAQ","SG9999014013.SGD","SG9999014039.USD","LU2210150020.SGD","BK4112","IE00BKPKM429.USD","LU2210149790.SGD","IE00B64PRP62.GBP","LU2095319765.USD","IE00BN0W2T93.GBP","SG9999014005.SGD","LU0314104364.USD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637354646","title":"Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637354646","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637354646?lang=en_us&edition=fundamental","pubTime":"2026-05-22 04:05","pubTimestamp":1779393900,"startTime":"0","endTime":"0","summary":"CONSHOHOCKEN, Pa., May  21, 2026  (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-assoc","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299716/0/en/Madrigal-Pharmaceuticals-Announces-Grants-of-Inducement-Awards-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4588","MDGL"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.madrigalpharma.com","stockEarnings":[{"period":"1week","weight":0.0244},{"period":"1month","weight":-0.0074},{"period":"3month","weight":0.1115},{"period":"6month","weight":-0.1483},{"period":"1year","weight":0.8143},{"period":"ytd","weight":-0.1183}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0162},{"period":"3month","weight":0.1169},{"period":"6month","weight":0.0626},{"period":"1year","weight":0.2223},{"period":"ytd","weight":0.0758}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.018335},{"month":2,"riseRate":0.7,"avgChangeRate":0.060749},{"month":3,"riseRate":0.3,"avgChangeRate":-0.012858},{"month":4,"riseRate":0.5,"avgChangeRate":0.006598},{"month":5,"riseRate":0.3,"avgChangeRate":0.113604},{"month":6,"riseRate":0.7,"avgChangeRate":0.032535},{"month":7,"riseRate":0.111111,"avgChangeRate":-0.07894},{"month":8,"riseRate":0.6,"avgChangeRate":0.097087},{"month":9,"riseRate":0.4,"avgChangeRate":0.124291},{"month":10,"riseRate":0.6,"avgChangeRate":0.054686},{"month":11,"riseRate":0.6,"avgChangeRate":0.099039},{"month":12,"riseRate":0.4,"avgChangeRate":0.372201}],"exchange":"NASDAQ","name":"Madrigal Pharmaceuticals","nameEN":"Madrigal Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Madrigal Pharmaceuticals,MDGL,Madrigal Pharmaceuticals股票,Madrigal Pharmaceuticals股票老虎,Madrigal Pharmaceuticals股票老虎国际,Madrigal Pharmaceuticals行情,Madrigal Pharmaceuticals股票行情,Madrigal Pharmaceuticals股价,Madrigal Pharmaceuticals股市,Madrigal Pharmaceuticals股票价格,Madrigal Pharmaceuticals股票交易,Madrigal Pharmaceuticals股票购买,Madrigal Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Madrigal Pharmaceuticals(MDGL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Madrigal Pharmaceuticals(MDGL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction